Conference Reports for NATAP

Back

HIV Research for Prevention (HIVR4P) October 21-25, 2018 Madrid     Anal Sex Frequent--and Often Condom-Free--in Global Female Sex Worker Study - Mark Mascolini (11/09/18)   New HIV Rate Remains "Alarmingly High" in MSM and TGW of Sub-Saharan Africa - Mark Mascolini (11/09/18)   One Year Retention in PrEPCare Outcomes in a Three-site Implementation Science Program in the United States - (11/06/18)   Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent - Mark Mascolini - (11/06/18)   Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy - Mark Mascolini - (11/06/18)   Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP - Mark Mascolini (11/06/18)   Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP) - (11/06/18)   PrEP New in Development & Current at HIVR4P - (11/06/18)   Global Update: State of Oral PrEP Implementation and Scale-up - (10/30/18)   Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques - (10/30/18)   Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/30/18)   Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis - (10/29/18)   Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services - (10/29/18)   Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017 - (10/29/18)   Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/29/18)   "AMP" PREP Broadly Neutralizing Antibody Studies / Next Generation PrEP / Tracking Global PrEP Use - (10/29/18)   Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last? - (10/26/18)   HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies - (10/26/18)   Long-term Delivery of Anti-HIV Monoclonal Antibodies with Gene Therapy Approach in Monkeys - (10/26/18)   Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077 - Mark Mascolini (10/25/18)   PER ACT HIV TRANSMISSION RISK THROUGH ANAL INTERCOURSE: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS1 - (10/25/18)   Tail-phase safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected individuals: HPTN 077 final results - Mark Mascolini - (10/25/18)   CDC- New HIV Infections / Ending AIDS by Tony Fauci at HIVR4P 2018 - (10/24/18)   Dapivirine Vaginal Ring Next Steps: Study Results Review, Planning for Introduction & Access, Regulatory Overview - (10/24/18)   HIV Transmission Rate 10 Times Higher With Anal vs Vaginal Sex: Meta-Analysis - Mark Mascolini (10/24/18)   Some Men With Urethritis Have HIV in Semen While Suppressed in Blood - Mark Mascolini (10/24/18)   Low-Dose Aspirin Cuts Inflammation in Blood and HIV Target Cells in Female Genital Tract - Mark Mascolini (10/24/18)   CD4s in "Normal" Anal Mucosa Are Activated in HIV+ Men With Anal Cancer Precursor - Mark Mascolini (10/24/18)